002022 科华生物
已收盘 09-08 15:00:00
资讯
新帖
简况
科华生物(002022)披露控股子公司产品获得医疗器械注册证,9月8日股价上涨2.25%
证券之星 · 09-08 17:59
科华生物(002022)披露控股子公司产品获得医疗器械注册证,9月8日股价上涨2.25%
股市必读:科华生物新发布《关于2026年员工持股计划证券账户开户完成的公告》
证券之星 · 09-07 01:43
股市必读:科华生物新发布《关于2026年员工持股计划证券账户开户完成的公告》
科华生物(002022)披露2026年员工持股计划证券账户开户完成公告,9月3日股价下跌1.03%
证券之星 · 09-03
科华生物(002022)披露2026年员工持股计划证券账户开户完成公告,9月3日股价下跌1.03%
股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年限制性股票激励计划首次授予相关事项的法律意见书》
证券之星 · 09-03
股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年限制性股票激励计划首次授予相关事项的法律意见书》
科华生物(002022)披露2026年限制性股票激励计划首次授予公告,9月1日股价上涨1.21%
证券之星 · 09-01
科华生物(002022)披露2026年限制性股票激励计划首次授予公告,9月1日股价上涨1.21%
股市必读:科华生物中报 - 第二季度单季净利润同比增长31.02%
证券之星 · 08-31
股市必读:科华生物中报 - 第二季度单季净利润同比增长31.02%
科华生物(002022)6月30日股东户数4.38万户,较上期减少9.36%
证券之星 · 08-28
科华生物(002022)6月30日股东户数4.38万户,较上期减少9.36%
图解科华生物中报:第二季度单季净利润同比增长31.02%
证券之星 · 08-28
图解科华生物中报:第二季度单季净利润同比增长31.02%
科华生物(002022.SZ)发布半年度业绩,归母净亏损1.04亿元
智通财经 · 08-27
科华生物(002022.SZ)发布半年度业绩,归母净亏损1.04亿元
公司问答丨科华生物:公司目前无针对甲醛检测的产品
格隆汇 · 08-27
公司问答丨科华生物:公司目前无针对甲醛检测的产品
科华生物:天隆公司提供食源性病原体检测项目
证券之星 · 08-27
科华生物:天隆公司提供食源性病原体检测项目
股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年第一次临时股东会之法律意见书》
证券之星 · 08-21
股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年第一次临时股东会之法律意见书》
科华生物(002022)披露2026年第一次临时股东会决议公告,8月19日股价下跌0.9%
证券之星 · 08-19
科华生物(002022)披露2026年第一次临时股东会决议公告,8月19日股价下跌0.9%
股市必读:科华生物新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见》
证券之星 · 08-17
股市必读:科华生物新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见》
科华生物(002022)披露2026年限制性股票激励计划首次授予激励对象名单公示情况说明及核查意见,8月13日股价上涨0.18%
证券之星 · 08-13
科华生物(002022)披露2026年限制性股票激励计划首次授予激励对象名单公示情况说明及核查意见,8月13日股价上涨0.18%
股市必读:科华生物(002022)8月12日董秘有最新回复
证券之星 · 08-13
股市必读:科华生物(002022)8月12日董秘有最新回复
科华生物:持续推进全价值链降本增效
证券之星 · 08-12
科华生物:持续推进全价值链降本增效
股市必读:科华生物新发布《关于产品获得医疗器械注册证的公告》
证券之星 · 08-07
股市必读:科华生物新发布《关于产品获得医疗器械注册证的公告》
科华生物(002022)披露产品获得医疗器械注册证公告,8月5日股价下跌0.96%
证券之星 · 08-05
科华生物(002022)披露产品获得医疗器械注册证公告,8月5日股价下跌0.96%
连续三年亏损叠加股价较高点最大跌幅超八成,科华生物拟推股权激励计划和员工持股计划
每日经济新闻 · 08-05
连续三年亏损叠加股价较高点最大跌幅超八成,科华生物拟推股权激励计划和员工持股计划
加载更多
公司概况
公司名称:
上海科华生物工程股份有限公司
所属行业:
医药制造业
上市日期:
2004-07-21
主营业务:
上海科华生物工程股份有限公司的主营业务是体外诊断试剂、仪器的研发、生产和销售。公司的主要产品是体外诊断试剂、仪器。
发行价格:
11.12
{"stockData":{"symbol":"002022","market":"SZ","secType":"STK","nameCN":"科华生物","latestPrice":5.9,"timestamp":1788851007000,"preClose":5.77,"halted":0,"volume":5001728,"delay":0,"changeRate":0.0225,"floatShares":513999999,"shares":513999999,"eps":-1.3656,"marketStatus":"已收盘","change":0.13,"latestTime":"09-08 15:00:00","open":5.74,"high":5.9,"low":5.72,"amount":29172300,"amplitude":0.0312,"askPrice":5.9,"askSize":492,"bidPrice":5.89,"bidSize":960,"shortable":0,"etf":0,"ttmEps":-1.3656,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.77,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":6.35,"lowLimit":5.19,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":514397174,"isCdr":false,"pbRate":1.2,"roa":"--","roe":"--","epsLYR":-1.4235,"committee":0.355566,"marketValue":3035000000,"turnoverRate":0.0097,"status":0,"floatMarketCap":3035000000},"requestUrl":"/m/hq/s/002022","defaultTab":"news","newsList":[{"id":"2665321622","title":"科华生物(002022)披露控股子公司产品获得医疗器械注册证,9月8日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665321622?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:59","pubTimestamp":1788861566,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘,科华生物报收于5.9元,较前一交易日上涨2.25%,最新总市值为30.35亿元。科华生物当日发布公告称,公司控股子公司苏州天隆生物科技有限公司近日收到国家药品监督管理局颁发的医疗器械注册证,产品为甲型/乙型流感及呼吸道合胞病毒核酸检测试剂盒,注册证编号国械注准20263401882,有效期至2031年9月3日。该试剂盒用于体外定性检测人口咽拭子样本中甲型流感、乙型流感以及呼吸道合胞病毒核酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","BK1574","BK1583","BK0028","BK0188","BK0239","09996","159883","BK0046","002022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665673553","title":"股市必读:科华生物新发布《关于2026年员工持股计划证券账户开户完成的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665673553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665673553?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:43","pubTimestamp":1788716588,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,科华生物报收于5.73元,下跌0.17%,换手率1.07%,成交量5.49万手,成交额3167.94万元。公司公告汇总:科华生物2026年员工持股计划证券账户已于8月26日开立完成,账户号码0899580126,截至9月4日尚未持有公司股票。交易信息汇总资金流向9月4日主力资金净流出11.34万元,占总成交额0.36%;游资资金净流入204.25万元,占总成交额6.45%;散户资金净流出192.91万元,占总成交额6.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0188","BK0239","161027","002022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664704138","title":"科华生物(002022)披露2026年员工持股计划证券账户开户完成公告,9月3日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664704138","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664704138?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:17","pubTimestamp":1788445035,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘,科华生物报收于5.74元,较前一交易日下跌1.03%,最新总市值为29.53亿元。近日,科华生物披露《关于2026年员工持股计划证券账户开户完成的公告》。截至2026年8月26日,公司2026年员工持股计划的证券账户已开立完成,账户名称为“上海科华生物工程股份有限公司-2026年员工持股计划”,账户号码为0899580126。截至公告日,该持股计划尚未持有公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300042377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","002022","BK0188","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846923","title":"股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年限制性股票激励计划首次授予相关事项的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664846923?lang=zh_cn&edition=full","pubTime":"2026-09-03 03:10","pubTimestamp":1788376220,"startTime":"0","endTime":"0","summary":"北京博星证券投资顾问有限公司关于上海科华生物工程股份有限公司2026年限制性股票激励计划首次授予事项的独立财务顾问报告独立财务顾问确认,科华生物于2026年9月1日召开董事会,确定向6名激励对象首次授予1,700.00万股限制性股票,授予价格为2.57元/股,股票来源为公司定向增发A股普通股;激励对象包括公司董事、高级管理人员,不含独立董事及持股5%以上股东;本次授予条件已成就,相关程序合规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002022","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664095857","title":"科华生物(002022)披露2026年限制性股票激励计划首次授予公告,9月1日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664095857","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664095857?lang=zh_cn&edition=full","pubTime":"2026-09-01 23:00","pubTimestamp":1788274844,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,科华生物报收于5.85元,较前一交易日上涨1.21%,最新总市值为30.09亿元。近日,上海科华生物工程股份有限公司发布《关于向2026年限制性股票激励计划激励对象首次授予限制性股票的公告》。本次授予对象包括公司董事、高级管理人员,不包括独立董事及持股5%以上股东。本激励计划有效期最长不超过60个月,首次授予部分分三年解除限售,解除限售比例分别为40%、30%、30%。本次授予条件已成就,相关审议程序及信息披露已完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","BK0188","002022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663627026","title":"股市必读:科华生物中报 - 第二季度单季净利润同比增长31.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663627026","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663627026?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:00","pubTimestamp":1788141620,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,科华生物报收于5.75元,上涨0.52%,换手率1.16%,成交量5.97万手,成交额3425.73万元。业绩披露要点:2026年中报显示归母净利润为-1.04亿元,同比上升22.24%;第二季度单季度归母净利润为-5531.57万元,同比上升31.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100006081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066151","title":"科华生物(002022)6月30日股东户数4.38万户,较上期减少9.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066151?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:46","pubTimestamp":1787910365,"startTime":"0","endTime":"0","summary":"证券之星消息,近日科华生物披露,截至2026年6月30日公司股东户数为4.38万户,较3月31日减少4524.0户,减幅为9.36%。在医疗器械行业个股中,科华生物股东户数高于行业平均水平,截至6月30日,医疗器械行业平均股东户数为2.12万户。从股价来看,2026年3月31日至2026年6月30日,科华生物区间跌幅为22.11%,在此期间股东户数减少4524.0户,减幅为9.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0028","002022","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662607087","title":"图解科华生物中报:第二季度单季净利润同比增长31.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662607087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662607087?lang=zh_cn&edition=full","pubTime":"2026-08-28 02:20","pubTimestamp":1787854856,"startTime":"0","endTime":"0","summary":"证券之星消息,科华生物2026年中报显示,上半年度公司主营收入8.38亿元,同比上升5.54%;归母净利润-1.04亿元,同比上升22.24%;扣非净利润-1.14亿元,同比上升18.82%;其中2026年第二季度,公司单季度主营收入4.42亿元,同比上升9.05%;单季度归母净利润-5531.57万元,同比上升31.02%;单季度扣非净利润-6214.14万元,同比上升25.32%;负债率33.19%,投资收益254.62万元,财务费用1665.72万元,毛利率36.73%。财报数据概要请见下图:本文数据来源于科华生物2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800005951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662180085","title":"科华生物(002022.SZ)发布半年度业绩,归母净亏损1.04亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662180085","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662180085?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:15","pubTimestamp":1787840121,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科华生物(002022.SZ)发布2026年半年度报告,报告期内,公司实现营业收入8.38亿元,同比增长5.54%;归属于上市公司股东的净亏损1.04亿元;归属于上市公司股东的扣除非经常性损益的净亏损1.14亿元;基本每股收益-0.2017元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"科华生物(002022.SZ)发布半年度业绩,归母净亏损1.04亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002022","BK0188","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773504","title":"公司问答丨科华生物:公司目前无针对甲醛检测的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773504","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773504?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:06","pubTimestamp":1787810778,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002022","BK0028","BK0239","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722202","title":"科华生物:天隆公司提供食源性病原体检测项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722202?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:36","pubTimestamp":1787801772,"startTime":"0","endTime":"0","summary":"证券之星消息,科华生物08月26日在投资者关系平台上答复投资者关心的问题。但在食品安全领域,公司控股子公司天隆公司可提供的相关检测产品,涵盖非洲猪瘟病毒、金黄色葡萄球菌、大肠杆菌等食源性病原体检测项目及猪、牛、羊等动物源性成分检测项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700025876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002022","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661360192","title":"股市必读:科华生物新发布《北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年第一次临时股东会之法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661360192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661360192?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:10","pubTimestamp":1787245824,"startTime":"0","endTime":"0","summary":"公司公告汇总北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2026年第一次临时股东会之法律意见书上海市金杜(广州)律师事务所对公司2026年第一次临时股东大会的召集和召开程序、出席人员资格、召集人资格、表决程序及表决结果出具法律意见。北京市金杜(广州)律师事务所对本次会议进行了见证并出具法律意见书,认为会议召集、召开程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002022","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421884","title":"科华生物(002022)披露2026年第一次临时股东会决议公告,8月19日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660421884?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:37","pubTimestamp":1787150232,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,科华生物报收于5.5元,较前一交易日下跌0.9%,最新总市值为28.29亿元。该股当日开盘5.52元,最高5.59元,最低5.47元,成交额达4096.04万元,换手率为1.44%。近日,上海科华生物工程股份有限公司发布2026年第一次临时股东会决议公告。会议采用现场投票与网络投票相结合的方式进行,出席股东代表股份占总股本的22.6270%。北京市金杜(广州)律师事务所对本次会议进行了见证并出具法律意见书,认为会议召集、召开程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002022","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660108682","title":"股市必读:科华生物新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660108682","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660108682?lang=zh_cn&edition=full","pubTime":"2026-08-17 03:43","pubTimestamp":1786909390,"startTime":"0","endTime":"0","summary":"公司公告汇总董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见公司于2026年8月4日至13日对2026年限制性股票激励计划首次授予激励对象姓名和职务进行内部公示,公示期间未收到异议;董事会薪酬与考核委员会核查确认激励对象主体资格合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","002022","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659163194","title":"科华生物(002022)披露2026年限制性股票激励计划首次授予激励对象名单公示情况说明及核查意见,8月13日股价上涨0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659163194","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659163194?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:42","pubTimestamp":1786632136,"startTime":"0","endTime":"0","summary":"近日,上海科华生物工程股份有限公司披露《董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见》。公告显示,公司于2026年8月3日召开第十届董事会第二十二次会议,审议通过《关于<2026年限制性股票激励计划(草案)>及摘要的议案》。公司对首次授予激励对象的姓名和职务在内部公示栏进行了公示,公示时间为2026年8月4日至8月13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300040027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002022","BK0028","BK0046","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659046349","title":"股市必读:科华生物(002022)8月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659046349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659046349?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:48","pubTimestamp":1786556895,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,科华生物报收于5.64元,上涨2.55%,换手率1.61%,成交量8.28万手,成交额4627.19万元。董秘最新回复投资者: 成本领先战略:通过大规模、高效率把成本做到行业最低。未来IVD行业只有以上3种企业能生存,董秘或董事会觉得贵公司属于哪一种?当日关注点交易信息汇总:8月12日主力资金净流入296.8万元,占总成交额6.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0188","002022","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658927440","title":"科华生物:持续推进全价值链降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2658927440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658927440?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:09","pubTimestamp":1786522147,"startTime":"0","endTime":"0","summary":"面对IVD行业集采政策持续落地执行、DRG/DIP支付方式加速落地、检验结果互认范围扩大、检验收费价格调整等多重政策压力及竞争加剧的市场环境,公司积极应对、主动调整,一方面,公司近年来持续推进全价值链降本增效,通过调整组织架构、精益管理优化资源配置效率,推动经营管理数智化转型,充分释放提质增效潜力,提升整体运营效能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200025680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002022","BK0046","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865453","title":"股市必读:科华生物新发布《关于产品获得医疗器械注册证的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865453","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657865453?lang=zh_cn&edition=full","pubTime":"2026-08-07 02:40","pubTimestamp":1786041624,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,科华生物报收于5.22元,上涨0.77%,换手率0.9%,成交量4.61万手,成交额2388.46万元。公司公告汇总关于产品获得医疗器械注册证的公告上海科华生物工程股份有限公司收到国家药品监督管理局颁发的医疗器械注册证,产品为淋球菌核酸检测试剂盒,注册证编号国械注准20263401679,有效期至2031年8月3日。该试剂盒用于体外定性检测男性尿道拭子、女性宫颈拭子样本中的淋球菌核酸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700002270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1583","BK1100","159883","002022","BK0188","BK0046","BK0239","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657435523","title":"科华生物(002022)披露产品获得医疗器械注册证公告,8月5日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657435523","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657435523?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:34","pubTimestamp":1785940458,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘,科华生物报收于5.18元,较前一交易日下跌0.96%,最新总市值为26.65亿元。该股当日开盘5.24元,最高5.28元,最低5.16元,成交额达3369.35万元,换手率为1.26%。近日,上海科华生物工程股份有限公司收到国家药品监督管理局颁发的医疗器械注册证,产品为淋球菌核酸检测试剂盒,注册证编号国械注准20263401679,有效期至2031年8月3日。该试剂盒用于体外定性检测男性尿道拭子、女性宫颈拭子样本中的淋球菌核酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1100","BK0028","002022","09996","BK1583","159883","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657951126","title":"连续三年亏损叠加股价较高点最大跌幅超八成,科华生物拟推股权激励计划和员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2657951126","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657951126?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:25","pubTimestamp":1785918300,"startTime":"0","endTime":"0","summary":"由于业绩持续下滑,科华生物的股价也持续走弱。相较于约六年前的高点,科华生物股价最大跌幅超过80%。2026年8月4日晚,科华生物发布了2026年限制性股票激励计划(草案)和2026年员工持股计划(草案)。若科华生物股权激励计划和员工持股计划皆按照上限成功实施且获得解锁,那么以8月4日收盘价计算,6位激励对象和220位核心员工所持股票浮盈规模将接近9000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-08-05/doc-inimhawc3617532.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-05/doc-inimhawc3617532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","002022","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788903119716,"stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.1153},{"period":"3month","weight":0.1614},{"period":"6month","weight":-0.0067},{"period":"1year","weight":-0.1424},{"period":"ytd","weight":-0.0067}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海科华生物工程股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"43825人(较上一季度减少75.90%)","perCapita":"11735股","listingDate":"2004-07-21","address":"上海市徐汇区钦州北路1189号","registeredCapital":"51439万元","survey":" 上海科华生物工程股份有限公司的主营业务是体外诊断试剂、仪器的研发、生产和销售。公司的主要产品是体外诊断试剂、仪器。","listedPrice":11.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科华生物(002022)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科华生物(002022)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科华生物,002022,科华生物股票,科华生物股票老虎,科华生物股票老虎国际,科华生物行情,科华生物股票行情,科华生物股价,科华生物股市,科华生物股票价格,科华生物股票交易,科华生物股票购买,科华生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科华生物(002022)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科华生物(002022)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}